AI assistant
Fluent, Inc. — Director's Dealing 2017
Dec 11, 2017
34456_dirs_2017-12-11_cb274f36-af41-4669-9b40-a8ba7c6f3422.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cogint, Inc. (COGT)
CIK: 0001460329
Period of Report: 2017-12-08
Reporting Person: FROST PHILLIP MD ET AL (Director, 10% Owner)
Reporting Person: Frost Gamma Investments Trust (10% Owner, Joint Filer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-12-08 | Common Stock | P | 10000 | $3.95 | Acquired | 15734874 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 3000000 | Indirect |
| Common Stock | 33333 | Direct |
| Common Stock | 16667 | Direct |
Footnotes
F1: The shares were purchased in multiple transactions at prices ranging from $3.93 to $3.98, with a weighted average price per share of $3.95. The reporting person undertakes to provide Cogint, Inc., any security holder of Cogint, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price with the ranges set forth in this footnote.
F2: These securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and
exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of
Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole
shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any
pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities
for purposes of Section 16 or for any other purpose.
F3: On December 8, 2015, the reporting person received a grant, subject to stockholder approval, of 3,000,000 RSUs, convertible into common stock of the issuer on a one-for-one basis. Stockholder approval was obtained on June 1, 2016. The reporting person has elected to defer delivery of any vested RSUs until the reporting person's separation from service from the Company, a Change of Control of the Company, or death or disability.
F4: Represents Restricted Stock Units (RSUs) convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in approximate equal installments on June 1, 2018 and 2019, subject to accelerated vesting under certain circumstances.